Mycobactin biosynthesis pathway

The **mycobactin biosynthesis pathway** is a metabolic pathway unique to mycobacteria—including *Mycobacterium tuberculosis*—that synthesizes the siderophore mycobactin, a molecule required for iron acquisition in iron-limited environments such as those encountered inside the host. The pathway involves a series of enzymatic steps encoded by the *mbt* gene cluster (mbtA–mbtN), with key enzymes like MbtA (a bifunctional ligase for salicylate activation), MbtI (a salicylate synthase), MbtK (an acyltransferase), and others forming a large nonribosomal peptide synthetase–polyketide synthase (NRPS–PKS) complex. Disruption of this pathway—by mutation or chemical inhibition—results in iron starvation, impaired growth, and strongly decreased virulence of *M. tuberculosis*. As such, multiple enzymes within this biosynthetic pathway are considered highly promising targets for novel antitubercular drugs[1][2][3][4][5][6][7]. **Clarification:** The "Mycobactin biosynthesis pathway" is *not* a single molecule or receptor, but a metabolic process involving numerous enzymes (such as MbtA, MbtI, MbtK, etc.). For structured drug-target data, the actual therapeutic targets are individual enzymes/proteins within this pathway[1][2][7]. Marking as **is_incorrect: true** because the canonical form for a drug target would be a specific protein (e.g., “Salicylate synthase (MbtI)”), not the whole pathway.

Inhibitors prevent iron acquisition by targeting key enzymatic steps, primarily by inhibiting MbtA or MbtI, thereby blocking mycobactin production essential for Mycobacterium tuberculosis virulence and growth[1][2][7][6].